Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Endometrial cancer.
- F. Amant, P. Moerman, P. Neven, D. Timmerman, E. van Limbergen, I. Vergote
- Medicine
- Lancet
- 2005
Each year, endometrial cancer develops in about 142,000 women worldwide, and an estimated 42,000 women die from this cancer. The typical age-incidence curve for endometrial cancer shows that most… Expand
Endometrial cancer
- F. Amant, P. Moerman, P. Neven, D. Timmerman, I. Vergote
- Medicine
- The Lancet
- 12 August 2005
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
- G. Sledge, M. Toi, +15 authors A. Llombart-cussac
- Medicine
- Journal of clinical oncology : official journal…
- 3 June 2017
Purpose MONARCH 2 ( ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with… Expand
Association analysis identifies 65 new breast cancer risk loci
- K. Michailidou, S. Lindström, +356 authors D. Easton
- Biology, Medicine
- Nature
- 23 October 2017
Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast… Expand
Adjuvant trastuzumab in HER2-positive breast cancer.
- J. Vanderhaegen, R. Paridaens, P. Neven
- Medicine
- The New England journal of medicine
- 2012
Dennis Slamon, M.D., Ph.D., Wolfgang Eiermann, M.D., Nicholas Robert, M.D., Tadeusz Pienkowski, M.D., Miguel Martin, M.D., Michael Press, M.D., Ph.D., John Mackey, M.D., John Glaspy, M.D., Arlene… Expand
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.
- H. Eidtmann, R. de Boer, +7 authors R. Coleman
- Medicine
- Annals of oncology : official journal of the…
- 1 November 2010
BACKGROUND
Aromatase inhibitors (AIs) are accepted as adjuvant therapy for postmenopausal women (PMW) with hormone-responsive early breast cancer (EBC) with superior efficacy to tamoxifen. However,… Expand
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.
- D. Slamon, P. Neven, +18 authors G. Jerusalem
- Medicine
- Journal of clinical oncology : official journal…
- 3 June 2018
Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer who were… Expand
Genome-wide association studies identify four ER negative–specific breast cancer risk loci
- M. García-Closas, F. Couch, +267 authors P. Kraft
- Biology, Medicine
- Nature Genetics
- 1 April 2013
Estrogen receptor (ER)-negative tumors represent 20–30% of all breast cancers, with a higher proportion occurring in younger women and women of African ancestry. The etiology and clinical behavior of… Expand
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
- X. Yang, J. Chang-Claude, +171 authors M. García‐Closas
- Medicine
- Journal of the National Cancer Institute
- 2 February 2011
BACKGROUND
Previous studies have suggested that breast cancer risk factors are associated with estrogen receptor (ER) and progesterone receptor (PR) expression status of the tumors.
METHODS
We… Expand
Breast cancer in pregnancy: recommendations of an international consensus meeting.
- F. Amant, S. Deckers, +18 authors A. Du Bois
- Medicine
- European journal of cancer
- 1 December 2010
PURPOSE
To provide guidance for clinicians about the diagnosis, staging and treatment of breast cancer occurring during an otherwise uncomplicated pregnancy.
METHODS
An international expert Panel… Expand